CPC C07J 71/0026 (2013.01) [A61K 31/566 (2013.01); A61K 31/58 (2013.01); A61K 47/61 (2017.08); A61K 47/6801 (2017.08); A61K 47/6803 (2017.08); A61K 47/6849 (2017.08); A61K 47/6889 (2017.08); A61K 47/6951 (2017.08); A61P 29/00 (2018.01); C07J 41/005 (2013.01); C07J 41/0088 (2013.01); C07J 71/0031 (2013.01)] | 29 Claims |
1. A compound, pharmaceutically acceptable salt, stereoisomer, regioisomer, or a mixture of regioisomers thereof of Formula (Va), (Vb), (Vc) or (Vd) respectively:
![]() wherein:
BA is an antibody or antigen binding fragment thereof;
RG1 and RG2 are independently a reactive group residue selected from the group consisting of
![]() ![]() wherein the
![]() indicates the atom through which the RG1 or RG2 is bonded to the adjacent groups in the formula;
PA is a payload residue;
AA2 is a dipeptide, tripeptide, or tetrapeptide residue comprising amino acid residues selected from alanine, valine, leucine, isoleucine, methionine, tryptophan, phenylalanine, proline, glycine, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine, histidine, and citrulline;
PAB is
![]() wherein the
![]() indicates the atom through which the PAB is bonded to the adjacent groups in the formula;
subscript e is an integer from 0 to 6;
subscript n is an integer from 1 to 30;
subscript p is 0 or 1;
subscript q is 0 or 1; and
HG is selected from the following:
(a)
![]() (b)
![]() (c)
![]() or
(d)
![]() wherein the
![]() indicates the atom through which the HG is bonded to the adjacent groups in the formula.
|